Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Pfizer

Status: Terminated

Conditions: Neuroblastoma

Treatments: Drug: lorlatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04753658

B7461036

Details and patient eligibility

About

The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Enrollment: 15 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
• HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
• Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion criteria

• Any patient who does not meet any of the inclusion criteria defined in the previous section.

Trial design

15 participants in 1 patient group

Pediatric Neuroblastoma Patients Treated with Lorlatinib

Treatment:

Drug: lorlatinib